CRISPR-Cas9 in vivo
Selected indexed studies
- A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. (Cell Rep, 2018) [PMID:29490262]
- CRISPR-Cas9 for cancer therapy: Opportunities and challenges. (Cancer Lett, 2019) [PMID:30684591]
- CRISPR-Cas9 knockin mice for genome editing and cancer modeling. (Cell, 2014) [PMID:25263330]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. (2018) pubmed
- CRISPR-Cas9 for cancer therapy: Opportunities and challenges. (2019) pubmed
- CRISPR-Cas9 knockin mice for genome editing and cancer modeling. (2014) pubmed
- In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration. (2016) pubmed
- In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges. (2021) pubmed
- CRISPR/Cas9 Genome Editing for Tissue-Specific In Vivo Targeting: Nanomaterials and Translational Perspective. (2023) pubmed
- CRISPR-Cas9-mediated homology-directed repair for precise gene editing. (2024) pubmed
- CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. (2021) pubmed
- Advances in CRISPR/Cas9 Technology for in Vivo Translation. (2019) pubmed
- Mitigating off-target effects in CRISPR/Cas9-mediated in vivo gene editing. (2020) pubmed